Join the club for FREE to access the whole archive and other member benefits.

ProMIS secures $20.4M to accelerate Alzheimer's antibody development

Lead antibody shows promising preclinical data & is set for clinical development


Key points from article :

ProMIS Neurosciences, an antibody therapeutics company, has closed a $20.4M private investment in public equity (PIPE) financing round.

The company develops antibody therapeutics that specifically target toxic misfolded proteins associated with neurodegenerative diseases.

ProMIS uses computational algorithms to identify disease-specific targets, minimizing the risk of cross-reactivity.

Proceeds from the PIPE financing will be used to advance the clinical development of PMN310, a lead candidate targeting toxic amyloid-beta oligomers in Alzheimer's.

ProMIS presented preclinical data supporting the potential therapeutic advantage of PMN310 for Alzheimer's in July.

The funding will also support ProMIS' working capital needs and general corporate expenses.

Mentioned in this article:

Click on resource name for more details.

ProMIS Neurosciences

Developing antibody-based therapies for neurodegenerative disorders

Topics mentioned on this page:
Investments, Mental Health
ProMIS secures $20.4M to accelerate Alzheimer's antibody development